Prolonged ex vivo culture of cord blood CD34 + cells facilitates myeloid and megakaryocytic engraftment in the non-obese diabetic severe combined immunodeficient mouse model

Alison M. Rice, Julie A. Wood, Christopher G. Milross, Cathryn J. Collins, Jamie Case, Marcus R. Vowels, Robert E. Nordon

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

A clinical goal for ex vivo expansion of cord blood (CB) CD34 + cells is to shorten the period of neutropenia and thrombocytopenia following myeloablative therapy and transplantation. Prolongation of cytokine expansion leads to the production of greater numbers of cells, and should have an impact on neutrophil and platelet recovery. Furthermore, expansion of CD34 + cells should support the continued production of neutrophils and platelets in the 6-week period following transplantation. We tested these hypotheses by characterization of the kinetics (human CD45 + cells in the blood) and phenotype (CD45, CD34, CD61, CD33, CD19 and CD3) of human engraftment in the non-obese diabetic severe combined immunodeficient mouse (NOD-SCID) following 7 or 14 d of ex vivo expansion of CB CD34 + cells. Mice transplanted with 14 d cells showed greater percentages of human CD45 + cells in the blood, bone marrow and spleen than mice transplanted with unexpanded cells or 7 d cells. Prolonging cytokine exposure of CD34 + cells and transplantation with increasing numbers of input cells facilitated the production of absolute numbers of CD34 +, CD33 +, CD61 + and CD19 + cells in vivo. Furthermore, analysis of SCID engrafting potential showed that prolongation of culture duration facilitates in vivo expansion of CD45 +, CD34 + and CD19 + cells after transplantation. It is anticipated that prolonged (2 weeks) ex vivo culture of CB will have a beneficial clinical effect.

Original languageEnglish (US)
Pages (from-to)433-443
Number of pages11
JournalBritish Journal of Haematology
Volume114
Issue number2
DOIs
StatePublished - 2001
Externally publishedYes

Fingerprint

Inbred NOD Mouse
SCID Mice
Fetal Blood
Blood Cells
Cell Transplantation
Neutrophils
Blood Platelets
Cell Count
Transplantation
Cytokines
Neutropenia
Thrombocytopenia
Spleen
Bone Marrow
Phenotype

Keywords

  • Cord blood
  • Engraftment
  • Ex vivo expansion
  • NOD-SCID mice
  • Stem cells

ASJC Scopus subject areas

  • Hematology

Cite this

Prolonged ex vivo culture of cord blood CD34 + cells facilitates myeloid and megakaryocytic engraftment in the non-obese diabetic severe combined immunodeficient mouse model. / Rice, Alison M.; Wood, Julie A.; Milross, Christopher G.; Collins, Cathryn J.; Case, Jamie; Vowels, Marcus R.; Nordon, Robert E.

In: British Journal of Haematology, Vol. 114, No. 2, 2001, p. 433-443.

Research output: Contribution to journalArticle

Rice, Alison M. ; Wood, Julie A. ; Milross, Christopher G. ; Collins, Cathryn J. ; Case, Jamie ; Vowels, Marcus R. ; Nordon, Robert E. / Prolonged ex vivo culture of cord blood CD34 + cells facilitates myeloid and megakaryocytic engraftment in the non-obese diabetic severe combined immunodeficient mouse model. In: British Journal of Haematology. 2001 ; Vol. 114, No. 2. pp. 433-443.
@article{1468b2fc28eb4176ad7b3909b3a40b25,
title = "Prolonged ex vivo culture of cord blood CD34 + cells facilitates myeloid and megakaryocytic engraftment in the non-obese diabetic severe combined immunodeficient mouse model",
abstract = "A clinical goal for ex vivo expansion of cord blood (CB) CD34 + cells is to shorten the period of neutropenia and thrombocytopenia following myeloablative therapy and transplantation. Prolongation of cytokine expansion leads to the production of greater numbers of cells, and should have an impact on neutrophil and platelet recovery. Furthermore, expansion of CD34 + cells should support the continued production of neutrophils and platelets in the 6-week period following transplantation. We tested these hypotheses by characterization of the kinetics (human CD45 + cells in the blood) and phenotype (CD45, CD34, CD61, CD33, CD19 and CD3) of human engraftment in the non-obese diabetic severe combined immunodeficient mouse (NOD-SCID) following 7 or 14 d of ex vivo expansion of CB CD34 + cells. Mice transplanted with 14 d cells showed greater percentages of human CD45 + cells in the blood, bone marrow and spleen than mice transplanted with unexpanded cells or 7 d cells. Prolonging cytokine exposure of CD34 + cells and transplantation with increasing numbers of input cells facilitated the production of absolute numbers of CD34 +, CD33 +, CD61 + and CD19 + cells in vivo. Furthermore, analysis of SCID engrafting potential showed that prolongation of culture duration facilitates in vivo expansion of CD45 +, CD34 + and CD19 + cells after transplantation. It is anticipated that prolonged (2 weeks) ex vivo culture of CB will have a beneficial clinical effect.",
keywords = "Cord blood, Engraftment, Ex vivo expansion, NOD-SCID mice, Stem cells",
author = "Rice, {Alison M.} and Wood, {Julie A.} and Milross, {Christopher G.} and Collins, {Cathryn J.} and Jamie Case and Vowels, {Marcus R.} and Nordon, {Robert E.}",
year = "2001",
doi = "10.1046/j.1365-2141.2001.02942.x",
language = "English (US)",
volume = "114",
pages = "433--443",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Prolonged ex vivo culture of cord blood CD34 + cells facilitates myeloid and megakaryocytic engraftment in the non-obese diabetic severe combined immunodeficient mouse model

AU - Rice, Alison M.

AU - Wood, Julie A.

AU - Milross, Christopher G.

AU - Collins, Cathryn J.

AU - Case, Jamie

AU - Vowels, Marcus R.

AU - Nordon, Robert E.

PY - 2001

Y1 - 2001

N2 - A clinical goal for ex vivo expansion of cord blood (CB) CD34 + cells is to shorten the period of neutropenia and thrombocytopenia following myeloablative therapy and transplantation. Prolongation of cytokine expansion leads to the production of greater numbers of cells, and should have an impact on neutrophil and platelet recovery. Furthermore, expansion of CD34 + cells should support the continued production of neutrophils and platelets in the 6-week period following transplantation. We tested these hypotheses by characterization of the kinetics (human CD45 + cells in the blood) and phenotype (CD45, CD34, CD61, CD33, CD19 and CD3) of human engraftment in the non-obese diabetic severe combined immunodeficient mouse (NOD-SCID) following 7 or 14 d of ex vivo expansion of CB CD34 + cells. Mice transplanted with 14 d cells showed greater percentages of human CD45 + cells in the blood, bone marrow and spleen than mice transplanted with unexpanded cells or 7 d cells. Prolonging cytokine exposure of CD34 + cells and transplantation with increasing numbers of input cells facilitated the production of absolute numbers of CD34 +, CD33 +, CD61 + and CD19 + cells in vivo. Furthermore, analysis of SCID engrafting potential showed that prolongation of culture duration facilitates in vivo expansion of CD45 +, CD34 + and CD19 + cells after transplantation. It is anticipated that prolonged (2 weeks) ex vivo culture of CB will have a beneficial clinical effect.

AB - A clinical goal for ex vivo expansion of cord blood (CB) CD34 + cells is to shorten the period of neutropenia and thrombocytopenia following myeloablative therapy and transplantation. Prolongation of cytokine expansion leads to the production of greater numbers of cells, and should have an impact on neutrophil and platelet recovery. Furthermore, expansion of CD34 + cells should support the continued production of neutrophils and platelets in the 6-week period following transplantation. We tested these hypotheses by characterization of the kinetics (human CD45 + cells in the blood) and phenotype (CD45, CD34, CD61, CD33, CD19 and CD3) of human engraftment in the non-obese diabetic severe combined immunodeficient mouse (NOD-SCID) following 7 or 14 d of ex vivo expansion of CB CD34 + cells. Mice transplanted with 14 d cells showed greater percentages of human CD45 + cells in the blood, bone marrow and spleen than mice transplanted with unexpanded cells or 7 d cells. Prolonging cytokine exposure of CD34 + cells and transplantation with increasing numbers of input cells facilitated the production of absolute numbers of CD34 +, CD33 +, CD61 + and CD19 + cells in vivo. Furthermore, analysis of SCID engrafting potential showed that prolongation of culture duration facilitates in vivo expansion of CD45 +, CD34 + and CD19 + cells after transplantation. It is anticipated that prolonged (2 weeks) ex vivo culture of CB will have a beneficial clinical effect.

KW - Cord blood

KW - Engraftment

KW - Ex vivo expansion

KW - NOD-SCID mice

KW - Stem cells

UR - http://www.scopus.com/inward/record.url?scp=0034882855&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034882855&partnerID=8YFLogxK

U2 - 10.1046/j.1365-2141.2001.02942.x

DO - 10.1046/j.1365-2141.2001.02942.x

M3 - Article

VL - 114

SP - 433

EP - 443

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 2

ER -